Maypro Industries’ AmealPeptide® Could Help Achieve New Blood Pressure Goal

PURCHASE, NY – A new landmark 9,300 subject clinical trial sponsored by the National Institutes of Health (NIH) confirmed a more intensive management of high blood pressure, with a target systolic blood pressure (SBP) goal of 120 millimeters of mercury (mmHg). This new goal reduced incidence rates of heart attack, heart failure, and stroke by almost a third and the risk of death by almost a quarter compared to the conventional target of 140 mmHg.

The study subjects were treated with a combination of two or three anti-hypertension drugs to achieve a target SBP of either 140 mmHg or 120 mmHg. The 120 mmHg group showed dramatic improvement in overall health. Therefore, a key takeaway from this study is effective prevention. Given the known side effects and high costs of hypertension drugs, natural alternatives that are clinically validated could also be considered a wise choice.

Supported by 30 published studies, AmealPeptide® helps maintain both systolic and diastolic blood pressure within healthy limits and promotes arterial elasticity.* The ingredient, which is sourced exclusively by Maypro Industries, is known for its main mechanism as an ACE (Angiotensin Converting Enzyme) inhibitor.

To illustrate AmealPeptide®’s clinical efficacy, a 2005 clinical study published in the British Journal of Nutrition, 131 volunteers with SBP above 140 mmHg, aged 30 to 57 received various doses of AmealPeptide®. The maximum reduction of SBP was 10.1 mmHg after six weeks. A 2011 study from Journal of Medicinal Food showed a reduction of SBP of 10.4 mmHg after four weeks. Another study from 2011, published in Atherosclerosis, looked at 70 patients aged 50-69 with untreated stage I hypertension who received 3.4 mg of VPP plus IPP for eight weeks. In the active group, SBP was reduced by as much as 11 mmHg.

 “We are encouraged by the NIH’s study, which showed that more intensive management of blood pressure, especially systolic blood pressure, reduced heart attacks and stroke,” said Dan Lifton, President of Maypro’s Proprietary Branded Ingredients Group.

“In addition to existing AmealPeptide® research, this study sends an important message to finished product manufacturers that developing products with clinically validated cardiovascular health-supportive ingredients, such as AmealPeptide®, can ultimately play a vital role in the health of American end-user consumers when part of a comprehensive approach to wellness.”

*These statements have not been evaluated by the Food & Drug Administration.These ingredients are not intended to diagnose, treat, cure or prevent any disease.

About Maypro

Headquartered in Purchase, NY and with offices in Tokyo and Shanghai, Maypro Group is a leading global supplier of specialty nutraceutical ingredients to the nutritional supplement, sports nutrition, pet and veterinary, cosmetic, functional food and fine chemical industries.  In addition to being a leading supplier of mainstream products such as CoQ10, fish oil, glucosamine and various botanical extracts, Maypro also markets a very strong portfolio of clinically validated proprietary and branded ingredients, representing some of the top manufacturers from Japan, Europe, and the United States.  For more information, please visit www.maypro.com. Click here for more information on AmealPeptide®.

For further information, please contact Jessica Szczechowicz at 914-251-0701 or Jessica@maypro.com